GMP – Page 33 – Pharma.Tips

WHO GMP gap identified during internal gap assessment – avoiding repeat WHO observations

Addressing Identified WHO GMP Gaps from Internal Assessments Pharmaceutical professionals know that maintaining compliance with WHO Good Manufacturing Practices (GMP) is not just about adhering to regulatory expectations; it also…

Equipment downtime due to cleaning during validation lifecycle – cycle time reduction with compliance assurance

Addressing Equipment Downtime from Cleaning in Validation Lifecycles for Enhanced Productivity In pharmaceutical manufacturing, equipment downtime due to cleaning during the validation lifecycle poses significant challenges to operational efficiency and…

Supplier WHO GMP non-compliance during internal gap assessment – CAPA aligned to WHO standards

Playbook for Addressing Supplier WHO GMP Non-Compliance During Internal Gap Assessments Supplier WHO GMP non-compliance can pose a significant risk to pharmaceutical manufacturers, especially during internal gap assessments. Addressing these…

Inadequate WHO GMP training during internal gap assessment – CAPA aligned to WHO standards

Addressing Insufficient WHO GMP Training in Internal Gap Assessments In the complex landscape of pharmaceutical manufacturing, ensuring compliance with WHO GMP standards is critical. Inadequate training during internal gap assessments…

API site WHO GMP risk during WHO inspection – avoiding repeat WHO observations

Mitigating API Site Risks During WHO Inspections: A Practical Playbook Pharmaceutical manufacturers face a growing imperative to maintain compliance with WHO Good Manufacturing Practice (GMP) standards. The increasing scrutiny during…

Inefficient CIP cycle during validation lifecycle – inspection-ready cleaning optimization

Addressing Challenges in CIP Cycle Inefficiencies During the Validation Lifecycle As pharmaceutical manufacturing processes continuously evolve, the demand for effective and efficient cleaning processes is emphasized, especially during the validation…

Repeated GMP deviations during internal audit – evidence package for inspection defense

Addressing Persistent GMP Deviations During Internal Audits: A Playbook for Compliance In the complex world of pharmaceutical manufacturing, repeated GMP deviations during internal audits can threaten product quality, regulatory standing,…

Uncontrolled SOP changes during scale-up – FDA/EMA inspection citation risk

Managing Uncontrolled SOP Changes During Scale-Up to Mitigate FDA/EMA Inspection Risks Uncontrolled changes to Standard Operating Procedures (SOPs) during scale-up can lead to significant compliance risks, resulting in potential citations…

Inadequate GMP training during scale-up – CAPA framework to prevent recurrence

Preventing Recurrences of Inadequate GMP Training During Scale-Up: A Comprehensive Playbook In the dynamic landscape of pharmaceutical manufacturing, inadequate GMP training during the scale-up phase can jeopardize both product quality…

Redundant cleaning steps during validation lifecycle – validated efficiency improvement

Improving Efficiency by Reducing Redundant Cleaning Steps in the Validation Lifecycle Pharmaceutical manufacturers often encounter challenges with redundant cleaning steps during equipment validation, which can lead to increased cycle times…

Inconsistent GMP interpretation during regulatory inspection – FDA/EMA inspection citation risk

“`html Strategies for Managing Inconsistent GMP Interpretation during Regulatory Inspections In the pharmaceutical manufacturing sector, inconsistent interpretations of Good Manufacturing Practices (GMP) during regulatory inspections can lead to serious risks,…

Uncontrolled SOP changes during scale-up – how to rebuild GMP maturity

Addressing Uncontrolled SOP Changes During Scale-Up to Enhance GMP Maturity In the highly regulated pharmaceutical environment, uncontrolled changes to Standard Operating Procedures (SOPs) during the scale-up phase can jeopardize both…